This study aims to determine the role of type B progesterone receptor gene polymorphisms as a risk factor for pelvic organ prolapse in Balinese women. This paired case-control study involves 29 patients with pelvic organ prolapse as the case group and 29 patients without pelvic organ prolapse as the control group. The study was conducted at Sanglah Hospital, Denpasar and the Integrated Biomedical Laboratory, Faculty of Medicine, Udayana University. Three milliliters of venous blood samples were taken from each patient and PCR examination was performed to determine the type b progesterone receptor gene polymorphisms. Risk assessment of the type b progesterone receptor gene polymorphism for pelvic organ prolapse was done by controlling for confounding variables, including age, parity, body mass index, occupation, menopausal status, and history of hysterectomy, through multiple logistic regression tests. The type b progesterone receptor gene polymorphism increased the risk of pelvic organ prolapse three times compared to non-prolapsed in Balinese women (OR 3.90, 95%CI 1.16-13.07, p = 0.023). After controlling for various confounding variables, type b progesterone receptor gene polymorphism still increased the risk of pelvic organ prolapse up to four times (AOR 4.54, 95%CI 1.16-17.68, p = 0.029). The type b progesterone receptor gene polymorphism significantly increases the risk of pelvic organ prolapse in Balinese women.
Dietz HP. Pelvic organ prolapse – a review. Australian Journal for General Practitioners. 2015; 44: 446-452.
Milart P, Woźniakowska E, Czuczwar P, Woźniak S. Pelvic organ prolapse in women: how is it diagnosed and treated currently? Prz menopauzalny= Menopause Rev. 2015; 14(3): 155.
Wilkins MF, Wu JM. Epidemiology of pelvic organ prolapse. Curr Obstet Gynecol Rep. 2016; 5(2): 119–23.
Kim CM, Jeon MJ, Chung DJ, Kim SK, Kim JW, Bai SW. Risk factors for pelvic organ prolapse. Int J Gynaecol Obstet. 2007; 98(3): 248-251.
Razzak L. Pathophysiology of Pelvic Organ Prolapse. In: Pelvic Floor Disorders. IntechOpen. 2018.
Ward RM, Velez Edwards DR, Edwards T, Giri A, Jerome RN, Wu JM. Genetic epidemiology of pelvic organ prolapse: a systematic review. Am J Obstet Gynecol. 2014; 211(4): 326-335.
Lim VF, Khoo JK, Wong V, Moore KH. Recent studies of genetic dysfunction in pelvic organ prolapse: the role of collagen defects. Aust New Zeal J Obstet Gynaecol. 2014; 54(3): 198–205.
Krissi H, Halperin R, Koren R, Peled Y. The presence and location of estrogen and progesterone receptors in the human pelvic cardinal ligaments. Pelviperineology. 2010; 29(1): 17–9.
Bai SW, Yoon JM, Shin JS, Kim SK, Park KH. Roles of estrogen receptor, progesterone receptor, p53 and p21 in pathogenesis of pelvic organ prolapse. Int Urogynecol J. 2005; 16(6): 492–6.
Karki R, Pandya D, Elston RC, Ferlini C. Defining “mutation” and “polymorphism” in the era of personal genomics. BMC Med Genomics. 2015; 8(1): 1–7.
Jacobsen BM, Horwitz KB. Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol. 2012; 357(1–2): 18–29.
Chen H-Y, Chung Y-W, Lin W-Y, Chen W-C, Tsai F-J, Tsai C-H. Progesterone receptor polymorphism is associated with pelvic organ prolapse risk. Acta Obstet Gynecol Scand. 2009; 88(7): 835–8.
Wu JM, Vaughan CP, Goode PS, Redden DT, Burgio KL, Richter HE, et al. Prevalence and trends of symptomatic pelvic floor disorders in US women. Obstet Gynecol. 2014; 123(1): 141.
Weintraub AY, Glinter H, Marcus-Braun N. Narrative review of the epidemiology, diagnosis and pathophysiology of pelvic organ prolapse. Int Braz J Urol. 2019; 46: 5–14.
Horst W, Do Valle JB, Silva JC, Gascho CLL. Pelvic organ prolapse: prevalence and risk factors in a Brazilian population. Int Urogynecol J. 2017; 28(8): 1165–70.
Fatima Q, Razzaqe H, Kashif M, Aslam F. Association of parity and pelvic organ prolapse. JRMC. 2016.
Vergeldt TFM, Weemhoff M, IntHout J, Kluivers KB. Risk factors for pelvic organ prolapse and its recurrence: a systematic review. Int Urogynecol J. 2015; 26(11): 1559–73.
Patel DA, Xu X, Thomason AD, Ransom SB, Ivy JS, DeLancey JO. Childbirth and pelvic floor dysfunction: an epidemiologic approach to the assessment of prevention opportunities at delivery. Am J Obstet Gynecol. 2006; 195(1): 23-28.
Forner LB, Beckman EM, Smith MD. Symptoms of pelvic organ prolapse in women who lift heavy weights for exercise: a cross-sectional survey. Int Urogynecol J. 2020; 31(8): 1551–8.
Koyuncu A, Kadota JL, Mnyippembe A, Njau PF, Sijali TR, McCoy SI, et al. Heavy Load Carrying and Symptoms of Pelvic Organ Prolapse among Women in Tanzania and Nepal: An Exploratory Study. Int J Environ Res Public Health. 2021; 18(3): 1279.
Young N, Atan IK, Rojas RG, Dietz HP. Obesity: how much does it matter for female pelvic organ prolapse? Int Urogynecol J. 2018; 29(8): 1129–34.
Orejuela FJ, Shek KL, Dietz HP. The time factor in the assessment of prolapse and levator ballooning. Int Urogynecol J. 2012; 23(2): 175–8.
Ramalingam K, Monga A. Obesity and pelvic floor dysfunction. Best Pract Res Clin Obstet Gynaecol. 2015; 29(4): 541–7.
de Sam Lazaro S, Nardos R, Caughey AB. Obesity and pelvic floor dysfunction: battling the bulge. Obstet Gynecol Surv. 2016; 71(2): 114–25.
Sze EHM, Hobbs G. A prospective cohort study of pelvic support changes among nulliparous, multiparous, and pre-and post-menopausal women. Eur J Obstet Gynecol Reprod Biol. 2012; 160(2): 232–5.
Forsgren C, Lundholm C, Johansson ALV, Cnattingius S, Zetterström J, Altman D. Vaginal hysterectomy and risk of pelvic organ prolapse and stress urinary incontinence surgery. Int Urogynecol J. 2012; 23(1): 43–8.
Lykke R, Løwenstein E, Blaakær J, Gimbel H. Hysterectomy technique and risk of pelvic organ prolapse repair: a Danish nationwide cohort study. Arch Gynecol Obstet. 2017; 296(3): 527–31.
Dallas K, Elliott CS, Syan R, Sohlberg E, Enemchukwu E, Rogo-Gupta L. Association between concomitant hysterectomy and repeat surgery for pelvic organ prolapse repair in a cohort of nearly 100,000 women. Obstet Gynecol. 2018; 132(6): 1328–36.
Zong W, Meyn LA, Moalli PA. The amount and activity of active matrix metalloproteinase 13 is suppressed by estradiol and progesterone in human pelvic floor fibroblasts. Biol Reprod. 2009; 80(2): 367–74.
This work is licensed under a Creative Commons Attribution 4.0 International License.